Fulvestrant: Clinical Trials

148 trials of Fulvestrant, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

43 completed, 39 recruiting, 17 active not recruiting, 16 terminated. 148 Phase 1, 56 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 1148Completed 43, Recruiting 39, Active not recruiting 17, Terminated 16, Withdrawn 12, Unknown 11, Not yet recruiting 10
Phase 256Recruiting 21, Withdrawn 8, Completed 7, Unknown 7, Active not recruiting 6, Terminated 4, Not yet recruiting 3

Follow Fulvestrant: new trials by email Literature Review of Fulvestrant trials Research Report on Fulvestrant

Trials (filtered) newest first · largest first

All 148 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Evaluate the Effects of GDC-4198 in Combination With Letrozole, Fulvestrant, or Giredestrant in Participants With Locally Advanced or Metastatic Hormone Receptor-Positive, HER2-Negatve Breast Cancer
GDC-4198, Fulvestrant, Letrozole - Advanced or Metastatic Breast Cancer
Phase 1Not yet recruitingGenentech, Inc.1652026-12-152026-11-05
Ph 1/2 Study to Evaluate Safety & Tolerability of FMC-242 Alone and in Combination in Adults With Advanced Solid Tumors
FMC-242, Trastuzumab (or biosimilar), Fulvestrant (or generic) - Locally Advanced Solid Tumor
Phase 1 / Phase 2Not yet recruitingFrontier Medicines Corporation2822026-12-012026-11-18
A Phase 1/1b Study of PRT13722 in Participants With Advanced HR+/HER2- Breast Cancer
PRT13722, Fulvestrant, Abemaciclib - Breast Cancer, Hormone-receptor-positive Breast Cancer
Phase 1RecruitingPrelude Therapeutics Incorporated2422026-11-162026-11-12
A Study to Learn About the Study Medicine Called PF-08165784 in People With PIK3CA-Mutated Advanced or Metastatic Solid Tumors
PF-08165784, Fulvestrant, Atirmociclib - Advanced Breast Cancer, Advanced or Metastatic Breast Cancer
Phase 1Not yet recruitingPfizer2682026-11-092026-11-18
A Phase 1/2a Study of K-1728 in Advanced Solid Tumors
K-1728, Fulvestrant, Palbociclib - Breast Neoplasms, Solid Tumors
Phase 1 / Phase 2RecruitingKymaThera, Inc.1102026-10-142026-11-17
Reversing InGuinal Hernia Trial: The Evaluation of Sex Hormones to Reverse Inguinal Hernias in Males
Fulvestrant, Anastrozole (ARIMIDEX™) - Inguinal Hernia Unilateral, Inguinal Hernia Without Obstruction or Gangrene
Phase 1RecruitingNorthwestern University302026-10-022026-11-16
A Study of AL58805 in Advanced, Metastatic GYN, STS or Breast Cancers
AL58805, AL8326, Eribulin - Endometrial Neoplasms, Soft Tissue Sarcoma (STS)
Phase 1 / Phase 2Not yet recruitingAdvenchen Pharmaceuticals, LLC.1382026-09-012026-09-10
A Study to Evaluate ATX-898 in Participants With Advanced Solid Tumors
ATX-898, ATX-898, fulvestrant, ribociclib - Advanced Solid Tumors
Phase 1 / Phase 2RecruitingAntares Therapeutics, Inc3432026-08-312026-10-16
A Study of LAE118 as Monotherapy and in Combination With Antitumor Agents in Advanced Solid Tumors
LAE118, Fulvestrant, Palbociclib - Patients With Advanced Solid Tumors
Phase 1Not yet recruitingLaekna Limited1502026-08-012026-08-26
Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
ERW316, Fulvestrant, Letrozole - Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors
Phase 1 / Phase 2WithdrawnNovartis Pharmaceuticals2026-06-302026-06-22
Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer
IEV407, Fulvestrant, Letrozole - Advanced HR+/HER2- Breast Cancer
Phase 1RecruitingNovartis Pharmaceuticals1942026-05-282026-11-03
Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer
Serabelisib, Sapanisertib, Fulvestrant - HR+ HER2- Breast Cancer
Phase 1 / Phase 2RecruitingFaeth Therapeutics322026-04-222026-11-18
A Study of HRS-6208 in Combination With HRS-8080, or Fulvestrant, or Letrozole, With or Without HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast Cancer
HRS-6208 Capsule, HRS-6209 Capsule, HRS-8080 Tablet - Advanced Unresectable or Metastatic Breast Cancer of Adults
Phase 1 / Phase 2RecruitingShandong Suncadia Medicine Co., Ltd.1802026-03-272026-04-03
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors
IDE574, Fulvestrant injection - Cancer
Phase 1RecruitingIDEAYA Biosciences1552026-03-172026-11-05
Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HLX97 (a KAT6A/B Inhibitor) in Patients With Advanced/Metastatic Solid Tumor
HLX97, Fulvestrant - Advanced/Metastatic Solid Tumors
Phase 1Not yet recruitingShanghai Henlius Biotech1382026-03-012026-03-18
Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer
BBI-940, Fulvestrant - Breast Cancer, Metastatic Breast Cancer
Phase 1TerminatedBoundless Bio, Inc.82026-02-252026-08-19
A Study of Single Dose of BL0175 in Postmenopausal Women
BL0175, Fulvestrant - Postmenopausal Women
Phase 1Not yet recruitingShanghai Best-Link Bioscience, LLC272026-01-262026-01-26
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
AMXT 1501 Dicaprate, DFMO, Fulvestrant - Melanoma (Skin Cancer), HER2-low Hormone Receptor Positive Breast Cancer
Phase 1 / Phase 2RecruitingAminex Therapeutics, Inc.922026-01-262026-10-22
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
GVV858, Fulvestrant, Letrozole - Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors
Phase 1 / Phase 2RecruitingNovartis Pharmaceuticals2052025-12-292026-10-29
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
PF-08032562, Fulvestrant, Cetuximab - Advanced Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-)
Phase 1RecruitingPfizer2602025-12-232026-11-05

Showing 20 of 148. Sign in to see all of them.

Conditions studied

Breast Neoplasms (96)  ·  Ovarian Neoplasms (12)  ·  Neoplasms (10)  ·  Neoplasm Metastasis (9)  ·  Endometrial Neoplasms (8)  ·  Triple Negative Breast Neoplasms (7)  ·  Carcinoma, Non-Small-Cell Lung (6)  ·  Hereditary Sensory and Autonomic Neuropathies (5)  ·  Prostatic Neoplasms (5)  ·  Carcinoma, Ovarian Epithelial (4)  ·  Squamous Cell Carcinoma of Head and Neck (4)  ·  Uterine Cervical Neoplasms (4)  ·  Breast Diseases (3)  ·  Colorectal Neoplasms (3)  ·  Neoplasms by Site (3)

Sponsors

AstraZeneca (8)  ·  Novartis Pharmaceuticals (8)  ·  Eli Lilly and Company (5)  ·  ImmunityBio, Inc. (5)  ·  BeOne Medicines (4)  ·  Memorial Sloan Kettering Cancer Center (4)  ·  Pfizer (4)  ·  Genentech, Inc. (3)  ·  Hoffmann-La Roche (3)  ·  Jiangsu HengRui Medicine Co., Ltd. (3)  ·  Mayo Clinic (3)  ·  National Cancer Institute (NCI) (3)  ·  Avenzo Therapeutics, Inc. (2)  ·  Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (2)  ·  Dana-Farber Cancer Institute (2)

Countries

United States (101)  ·  China (25)  ·  France (25)  ·  Spain (25)  ·  United Kingdom (20)  ·  Australia (18)  ·  South Korea (14)  ·  Canada (13)  ·  Japan (13)  ·  Italy (12)  ·  Germany (9)  ·  Singapore (7)  ·  Belgium (6)  ·  Denmark (5)  ·  Taiwan (5)

Top investigators

Cynthia Ma (2)  ·  Adrian J Hepner, MD, PhD (1)  ·  Adrienne G Waks, MD (1)  ·  Alison Schram, MD (1)  ·  Amy J Chien, MD (1)  ·  Amy Tiersten, MD (1)  ·  Ana Gonzalez-Angulo, MD, MS (1)  ·  Anja Wiliams (1)

Results publications

PMID 32385714, PMID 24919854, PMID 25002028, PMID 28540640, PMID 29401002, PMID 30543347, PMID 31235441, PMID 32035020, PMID 32234755, PMID 32619077, PMID 32887722, PMID 33641211, PMID 33660194, PMID 34726887, PMID 35223458, PMID 35235412, PMID 35321427, PMID 35440569, PMID 35671774, PMID 36913051, PMID 36970876, PMID 37488191, PMID 37507802, PMID 37580773, PMID 38439079, PMID 38547892, PMID 38753757, PMID 38937298, PMID 39229468, PMID 39236276, PMID 40627530, PMID 40743286, PMID 41271741, PMID 42061370, PMID 42421507

NIH funding

2016 (6), 2025 (6), 2023 (5), 2017 (4), 2015 (2), UM1CA186704 (2), 2019 (1), N01CM00099 (1), P30CA015083 (1), P30CA091842 (1), R01CA255960 (1), UM1CA186689 (1)